AGIO vs GMAB: fair value comparison
Agios Pharmaceuticals, Inc. and Genmab A/S · Updated 2026-10-19
AGIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, GMAB currently ranks higher by quality score.
| AGIO | GMAB | |
|---|---|---|
| Verdict | No estimate yet | Overvalued |
| Last price | $31.32 | $37.00 |
| 12-month range | $22.34–$45.49 | $23.85–$38.48 |
| Rank by discount to fair value | — | #76 of 108 Healthcare |
| Rank by quality score | #93 of 301 Healthcare | #91 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: AGIO fair value analysis · GMAB fair value analysis